Related by context. All words. (Click for frequent words.) 87 randomized double 83 blind randomized placebo 82 placebo controlled 80 randomized placebo controlled 77 blind randomized 76 blind placebo controlled 76 randomized controlled 73 randomized 73 double blinded placebo 73 multicenter randomized double 72 multicenter 71 prospective randomized 71 double blinded randomized 70 placebo controlled randomized 70 randomized clinical 70 prospective randomized placebo 69 dose escalation study 69 dose escalation trial 69 randomized multicenter 69 Phase IIa 68 placebo controlled Phase 68 Phase III randomized 67 multicenter randomized 67 placebo controlled clinical 67 multicentre 67 Phase 2b study 67 randomized controlled trial 67 blinded placebo controlled 66 Phase IIb 66 Phase 2a clinical 66 active comparator 66 Phase 2b trial 66 Phase 1b clinical 66 Phase 2b clinical 66 multicentre randomized double 65 clinical trial 65 randomized controlled clinical 65 tolerability 65 Phase IIb trial 65 single ascending dose 65 Phase III clinical 65 prospective randomized controlled 64 placebo controlled Phase III 64 controlled multicenter 64 randomized blinded 64 multicentre randomized 64 safety tolerability 64 Phase Ib clinical 64 label multicenter 64 blinded randomized placebo controlled 64 Phase Ib 63 multicenter study 63 multiple ascending dose 63 phase IIa 63 randomized Phase III 63 Phase IIb clinical 63 Phase 1b trial 63 multicenter randomized placebo controlled 63 pivotal Phase III 63 prospective observational 63 Phase IIa clinical 63 placebo controlled studies 63 TMC# C# 63 pharmacokinetics 63 Phase III placebo controlled 63 label dose escalation 63 blinded randomized 63 dose dose escalation 63 Phase 2b 63 multicenter placebo controlled 62 phase IIb 62 phase IIb clinical 62 pharmacokinetic 62 safety tolerability pharmacokinetics 62 blind placebo 62 phase IIa clinical 62 phase Ib 62 Phase IIa trial 62 ascending dose 62 Phase 2a 62 prospective cohort 62 randomized blinded placebo 62 pivotal Phase 62 blind multicenter 61 pharmacokinetics PK 61 masked placebo controlled 61 ascending doses 61 Phase IIIb 61 multicenter randomized controlled 61 randomized Phase 61 multicenter clinical 61 dose regimens 61 Phase 2a trial 61 multicenter Phase II 61 prospective randomized multicenter 61 prospective multicenter 61 Phase 1b 61 multicenter prospective 60 randomized crossover 60 dose escalation 60 multicenter Phase 60 Phase 1a 60 phase 2a 60 Phase III 60 randomized #:# 60 observer blinded randomized 60 dose escalation Phase 60 blind randomized controlled 60 pharmacodynamics 60 nonrandomized 60 Phase Ia 60 multicenter Phase III 60 placebo controlled dose escalation 60 HCV SPRINT 60 multicenter phase 60 placebo controlled trials 60 randomized controlled trials 60 multicenter multinational 59 dosing cohorts 59 mg dose 59 dose cohorts 59 randomized clinical trials 59 NO# [002] 59 analgesic efficacy 59 dyskinesia PD LID 59 controlled dose escalation 59 Randomized 59 Phase IIIb clinical 59 TG MV 58 observational study 58 placebo controlled clinical trials 58 dose escalation clinical 58 Phase III randomized placebo 58 trials RCTs 58 Randomized Double blind 58 Placebo controlled 58 pharmacodynamic profile 58 Phase III clinical trials 58 AIR CF1 58 pharmacokinetic profile 58 diabetic neuropathic pain 58 Randomized Double Blind Placebo 58 ADVANCE PD 58 dosing regimens 57 randomized multicenter trial 57 phase IIb trial 57 PRE SURGE 57 TAXUS ATLAS 57 label multicenter Phase 57 randomized controlled clinical trials 57 randomized multicentre 57 Traficet EN 57 Randomised 57 HCV RESPOND 2 57 mg administered orally 57 RE LY ® 57 subanalysis 57 randomized trials 57 randomized controlled Phase 57 viral kinetic 57 investigational oral 57 randomized placebo 57 Initiated Phase 57 safety tolerability pharmacokinetic 57 landmark ATHENA 56 LUX Lung 56 Sorafenib HCC Assessment 56 Phase 2b randomized 56 Phase III pivotal 56 ACTEMRA TM 56 relapsing remitting multiple sclerosis 56 PRECiSE 56 phase IIIb 56 oral rivaroxaban 56 Phase #/#a 56 EURIDIS 56 prospective multicenter randomized 56 primary endpoint 56 ritonavir boosted 56 Clinical Antipsychotic Trials 56 treatment naive genotype 56 randomized Phase IIb 56 pharmacokinetic PK 56 pharmacokinetic studies 56 prospectively randomized 56 lubiprostone 56 symptomatic BPH 56 treatment naïve genotype 56 telaprevir dosing 56 dosage regimens 56 mg BID 56 Phase IIIb study 56 dose titration 56 RG# ITMN 56 prospective nonrandomized 56 phase IIb study 56 LEXIVA r 56 Intervention Effectiveness 56 FAME Study 56 HPTN 56 Randomized Phase 56 Randomized controlled 56 nab paclitaxel 56 vicriviroc 56 Phase Ib II 56 COMFORT II 56 TRANSFORMS 55 tolerability pharmacokinetics 55 Phase III multicenter 55 multicentre study 55 ExTRACT TIMI 55 longitudinal cohort study 55 PREZISTA r 55 Multicenter 55 KRN# 55 BRIM3 55 pharmacodynamic 55 Study ADX# 55 #mg/day [001] 55 AIR CF2 55 ONTARGET 55 nitazoxanide 55 AZILECT R 55 PRTX 55 Phase III trials 55 Phase Ib study 55 BOLDER II 55 SCH # 55 APEX PD 55 APTIVUS 55 riociguat 55 refractory CLL 55 CRx 55 non inferiority 55 DURATION 55 comparing XIENCE V 55 Parkinson disease levodopa induced 55 subcutaneously administered 55 evaluable patients 55 desvenlafaxine succinate 55 teriflunomide 55 VICTOR E1 55 pharmacokinetic PK study 55 Phase IIb Trial 55 dose regimen 55 Phase Ib clinical trials 55 Tolvaptan 55 CAMMS# 55 randomized controlled multicenter 55 BR.# 55 dosing 55 Phase III Clinical Trial 55 Pivotal Trial 55 clinical trials 55 Phase 1a clinical 55 tolerability profile 54 label dose titration 54 BRIM2 54 EQUIP OB 54 Phase IIA 54 thorough QT 54 clinical pharmacology studies 54 bendamustine 54 coadministration 54 mg doses 54 peginterferon alfa 2b 54 primary hypercholesterolemia 54 RSD# oral 54 CLL8 54 label multicenter randomized 54 fluticasone furoate 54 Phase IIB 54 CLARITY study 54 INCB# [001] 54 dose placebo controlled 54 SPIRIT III 54 risperidone Risperdal 54 Phase IIa trials 54 tanespimycin 54 dose escalation phase 54 substudy 54 mg QD 54 prucalopride 54 Phase #b/#a 54 oral deforolimus 54 Phase 2b clinical trials 54 MEND CABG 54 PRECISE 54 ascending dose study 54 pharmacokinetic pharmacodynamic 54 dosing regimen 54 Prostate Lung Colorectal 54 citalopram 54 davunetide intranasal AL 54 primary efficacy endpoint 54 Phase III randomized controlled 54 HOPE TOO 54 randomized Phase 2b 54 mg RDEA# 54 EDEMA3 54 multinational multicenter randomized 54 forodesine 54 tolerated dose MTD 54 APTIVUS r 54 Multiple Ascending Dose 54 Initiate Phase 54 pegylated interferon alfa 2a 54 randomized multicenter Phase III 54 investigational drug 54 RoACTEMRA 54 antiretroviral naive 54 Phase IIb trials 54 posaconazole 54 huC# DM4 54 phase Ib clinical 54 PRX # 54 GAMMAGARD 54 Phase II 54 IIa clinical trial 54 pharmacodynamics PD 54 relapsed MM 54 NGX# 54 investigational compound 54 REYATAZ r 54 monotherapy 54 Cardiac Allograft Rejection 54 lacosamide 53 Efficacy 53 II Clinical Trial 53 HCV infected 53 EVEREST II 53 bosentan 53 Val HeFT 53 Dacogen injection 53 ACTEMRA 53 Controlled Trial 53 ISIS # 53 teduglutide 53 Laquinimod 53 SPIRIT IV 53 zonisamide SR 53 Matrix Phase 2b 53 SPIRIT FIRST 53 DermaVir Patch 53 placebo 53 Pivotal Phase 53 darunavir ritonavir 53 Betaferon ® 53 Edge STudy 53 evaluating REVLIMID 53 ENESTnd 53 prospective multicentre 53 sunitinib malate 53 observational studies 53 ZYBRESTAT fosbretabulin 53 ORMD 53 CHAMPION PCI 53 Denufosol 53 administered subcutaneously 53 Randomized Evaluation 53 OPT CHF 53 dosing cohort 53 efficacy 53 REVLIMID lenalidomide 53 blind multicentre 53 visilizumab 53 Double Blind Placebo 53 relapsed myeloma 53 oral formulation 53 phase III ACCLAIM 53 ADAGIO study 53 Phase IIb III 53 LibiGel Phase III 53 hour bronchodilation 53 MERLIN TIMI 53 Zenvia ™ 53 registrational 53 cetrorelix 53 etanercept 53 Amrubicin 53 ABSORB clinical 53 OLYMPIA registry 53 RE SURGE 53 relapsed refractory multiple myeloma 53 AEGR 53 ANCHOR trial 53 Phase III confirmatory 53 telaprevir dosed 53 candesartan cilexetil 53 prospectively defined 53 ACTIVE W 53 post hoc 53 Dabigatran etexilate 53 viral kinetics 53 atorvastatin Lipitor 53 Androxal TM 53 noninferiority 53 ROCKET AF 53 icatibant 53 pramlintide 53 Placebo Controlled 53 RECORD1 53 TAXUS IV 53 #:# randomization 53 docetaxel Taxotere R 53 DAPT 53 mg/m2 dose 53 #mg QD [002] 53 rALLy clinical trial 53 IIa trial 53 GetGoal Phase III 53 DDP# 53 DASISION 53 #mg dose [001] 53 plus ribavirin 53 RE LY 53 Pivotal Phase III 53 NATRECOR ® 53 secondary efficacy endpoints 52 PEG INTRON R 52 RRMS patients 52 MAGE A3 ASCI 52 pimecrolimus cream 52 PEGINTRON TM 52 oral prodrug 52 SEROQUEL 52 pivotal bioequivalence 52 CTA# Injection 52 APPRAISE 52 beta2 agonist 52 efavirenz EFV 52 serotonin norepinephrine reuptake inhibitor 52 metreleptin 52 CANCIDAS 52 AIR CF3 52 lexidronam injection 52 TMC# r 52 RG# [001] 52 multicenter randomized clinical 52 eculizumab 52 eosinophilic asthma 52 Teriflunomide 52 buprenorphine naloxone 52 Phase III psoriasis 52 registrational Phase 52 REALITY Trial 52 TMC# [001] 52 mGluR5 NAM 52 functional dyspepsia 52 plus Copegus R 52 dabigatran etexilate 52 INCB# [003] 52 Ophena TM 52 insulin detemir 52 FOSRENOL R 52 STEALTH C 52 Sapacitabine 52 elotuzumab 52 Phase III Clinical Trials 52 evaluating tivozanib 52 confirmatory Phase III 52 NOXAFIL 52 Sym# 52 LCP AtorFen 52 ADX# 52 International Verapamil SR 52 cell lymphoma CTCL 52 PEG PAL 52 headache nasopharyngitis 52 Microplasmin 52 mGluR5 negative 52 pharmacokinetics pharmacodynamics 52 ABSORB trial 52 azacitidine 52 oral ridaforolimus 52 EQUATE OB 52 Clinical Trial 52 EFAPROXYN 52 mcg kg 52 pitavastatin 52 INSPIRE Trial Phase III 52 Acute Ischemic Stroke 52 fostamatinib 52 inhalations twice 52 relapsing multiple sclerosis 52 dose cohort 52 olanzapine Zyprexa 52 R#/MEM # 52 hyperphenylalaninemia HPA due 52 LITHE 52 NOXAFIL Oral Suspension 52 tocilizumab 52 Phase 1b dose escalation 52 IIa clinical 52 CIMZIA TM certolizumab pegol 52 unblinded 52 ORACLE MS 52 phase IIb III 52 Phase 1b clinical trials 52 Clinical Study 52 randomized #:#:# 52 Myocardial Infarction Study 52 controlled multicenter Phase 52 Intervention Trial GAIT 52 aripiprazole 52 EchoCRT 52 KAPIDEX 52 HCV NS5B polymerase 52 Degarelix 52 JAK inhibitor 52 Dose Ranging Study 52 telmisartan 52 antiviral activity 52 interferon gamma 1b 52 secondary endpoints 52 μg dose 52 irbesartan 52 ENDEAVOR IV 52 ENDEAVOR II 52 ARIXTRA 52 sorafenib Nexavar 52 SRT# [003] 52 8mg/kg 52 pharmacodynamic PD 52 adjunctive placebo 52 Prostate AdenoCarcinoma Treatment 52 galiximab 52 dirucotide MBP# 52 Paxil paroxetine 52 CATIE AD 52 multicenter randomized Phase 52 alvimopan 52 RLAI 52 Elagolix 52 relapsing remitting MS 52 Testosterone MDTS ® 52 LEVADEX 52 oral FTY# 52 rosuvastatin 52 perampanel 52 dose pharmacokinetic 52 CERVARIX 51 demonstrated statistically significant 51 multicentre prospective 51 GATTEX ™ 51 Phase IIb randomized 51 Phase Ib IIa 51 ATACAND 51 Trandolapril 51 peginterferon alfa 2a 51 eltrombopag 51 n = 51 edoxaban 51 Phenoptin 51 aripiprazole Abilify 51 DSMB 51 Blind Placebo Controlled Trial 51 FOLOTYN ® 51 pegylated interferon 51 inhibitor RG# 51 ocular hypertension 51 Tekturna HCT 51 hypogonadal men 51 Hypoactive Sexual Desire Disorder 51 mcg dose 51 MIVI III 51 pregabalin Lyrica 51 de novo kidney transplant 51 #mg BID [001] 51 efficacy tolerability 51 randomly assigned 51 interferon beta 1b 51 secondary endpoint 51 prasterone 51 boosted protease inhibitor 51 EXPAREL TM 51 placebo controlled multicenter 51 cannabinor 51 Phase 2b dose 51 celgosivir 51 CRESTOR #mg 51 VIRAMUNE XR 51 recurrent glioblastoma multiforme 51 ritonavir boosted atazanavir 51 ENVISION 51 CUSTOM II 51 ongoing Phase 1b 51 AIR2 Trial 51 Adalimumab 51 CIMZIA TM 51 Zavesca R 51 MSI #F 51 ToGA 51 Locteron ® 51 pomalidomide 51 Multicenter Randomized Double 51 weekly subcutaneous injections 51 Carotid Revascularization Endarterectomy vs. 51 confirmatory clinical 51 oral ibandronate 51 dose limiting toxicities 51 IPX# 51 Metabolic Efficiency 51 VA# [002] 51 comparator arm 51 Phase III Pivotal 51 retrospective cohort study 51 Safinamide 51 superficial bladder cancer 51 ECASS 51 zolmitriptan 51 REG2 51 plus prednisone 51 immunogenicity 51 DPNP 51 postmenopausal women 51 dosing schedules 51 opioid induced bowel dysfunction 51 diarrhea predominant irritable 51 maximally tolerated dose 51 heFH 51 Board DSMB 51 XIENCE V Stent System 51 ACCOMPLISH 51 DLTs 51 Trial Evaluating 51 Medidur TM FA 51 NP2 Enkephalin 51 QLT# 51 Oral Fingolimod 51 glatiramer acetate 51 metastatic hormone refractory 51 patients evaluable 51 FOSRENOL ® 51 IBS C 51 fosbretabulin 51 ofatumumab 51 Oral NKTR 51 albinterferon alfa 2b 51 colesevelam HCl 51 CONQUER OB 51 acyclovir Lauriad R 51 adalimumab 51 pancreatic neuroendocrine tumors 51 registrational trial 51 miconazole Lauriad ® 51 Controlled Study 51 laquinimod 51 #mg dose [003] 51 adjunctive ABILIFY 51 NCCTG 51 tiotropium 51 BENICAR HCT 51 LIALDA 51 observational cohort study 51 ZYBRESTAT 51 rotigotine 51 Dapagliflozin 51 liposomal formulation 51 GOUT 51 desvenlafaxine 51 ragweed allergic 51 opioid naive 51 varespladib 51 6R BH4 51 JANUVIA 51 recurrent GBM 51 Pegasys ® 51 dexpramipexole 51 plus dexamethasone 51 GLYX 51 HBeAg positive 51 tezampanel 51 VADT 51 Phase 51 mg d 51 STRIDE PD 51 polymerase inhibitor 51 intermittent dosing 51 Phase III VISTA 51 PREZISTA ritonavir 51 TAXUS VI 51 #mg BID [003] 51 receptor tyrosine kinase inhibitor 51 Phase IIb IIIa 51 mixed dyslipidemia 51 efficacy endpoints 51 pharmacokinetic parameters 51 EXPLORE Xa 51 ORENCIA ® 51 pegylated interferon alfa 2b 51 ABC/3TC 51 angiotensin receptor blocker ARB 51 Tanespimycin 51 LEXIVA 51 meta analysis 51 metformin HCl 51 retrospective observational study 51 antiretroviral naïve 51 painful diabetic neuropathy 51 pharmacokinetic PK profile 51 Randomized Controlled 51 RE LY trial 51 DU #b 51 subcutaneous formulation 51 solifenacin 51 intravenous dosing 51 COPAXONE R 51 QD dosing 51 blinded placebo 51 ISENTRESS 51 rFVIIa 51 brivaracetam 51 RIO Lipids 50 REVIVE Diabetes 50 migraine prophylaxis 50 events AEs 50 afatinib 50 Pharmacokinetics PK 50 CRLX# 50 Prostate Cancer Prevention 50 primary endpoints 50 confirmatory Phase 3 50 alvespimycin 50 protease inhibitor PI 50 DIRECT Trial 50 Phase 2b kidney transplant 50 safinamide 50 Tarceva TM 50 null responder HCV 50 Pivotal Study 50 PFO migraine 50 Double Blind Randomized 50 Taxotere ® 50 trastuzumab emtansine T DM1 50 baminercept 50 bepotastine besilate nasal spray 50 #mg [003] 50 venlafaxine XR 50 PD LID 50 ILLUMINATE 50 acute mania 50 Tocilizumab 50 patients undergoing percutaneous 50 RSD# 50 ataluren 50 severe psoriasis 50 R# #mg BID 50 Aryplase 50 IMGN# 50 oxycodone CR 50 PROMACTA 50 ARCOXIA 50 Randomized Double Blind 50 Acute Coronary Syndromes ACS 50 Study Evaluating 50 ASCEND HF 50 bicifadine 50 CALGB 50 long acting muscarinic 50 NSABP B 50 RezularTM 50 lomitapide 50 Fx #A 50 XYZAL R 50 trabedersen 50 EFFEXOR XR 50 PREVAIL 50 cathepsin K inhibitor 50 Pharmacokinetic 50 glycopyrrolate 50 Blind Placebo Controlled 50 evaluable 50 number NCT# ClinicalTrials.gov 50 European Sepsis Trial 50 SANTE 50 Multaq R 50 mg 50 mcg QD 50 HZT 50 relapsing remitting MS RRMS 50 PHX# 50 tacrolimus ointment 50 #mg/m# [002] 50 Wisconsin Sleep Cohort 50 Scandinavian Simvastatin Survival 50 virus HCV protease inhibitor 50 albiglutide 50 ROZEREM TM 50 Combination REOLYSIN R 50 bupropion SR 50 teriparatide 50 retrospective cohort 50 MIST II 50 Methylnaltrexone 50 μg kg 50 PRIMO CABG 50 blind randomized multicenter 50 mGluR2 positive 50 MEVACOR 50 methotrexate MTX 50 Ranolazine 50 Xanafide 50 GSK# [001] 50 sunitinib 50 PSN# [002] 50 pramipexole 50 multicentre randomized controlled 50 REYATAZ ritonavir 50 initiate Phase 50 Proellex TM 50 paclitaxel poliglumex 50 designated HVTN 50 pharmacokinetic characteristics 50 CURRENT OASIS 7 50 evaluating Vectibix 50 low dose cytarabine 50 eszopiclone 50 Enzastaurin 50 Secondary endpoints 50 antiviral efficacy 50 certolizumab pegol 50 Zerenex 50 MIRAPEX ER 50 EOquin TM 50 intravenous dose 50 metastatic HRPC 50 AZX# 50 intravenously administered 50 cilostazol 50 ELND# 50 BOLDER 50 resminostat 50 melphalan prednisone 50 CCR5 antagonist 50 IDX# 50 Contrave# 50 Bronchitol 50 SCIg 50 GATTEX ® 50 atrasentan 50 Lamictal XR 50 BoNTA 50 docetaxel 50 ALISTA 50 tolvaptan 50 IV bolus 50 unblinding 50 cetrorelix pamoate 50 ziprasidone Geodon 50 invasive candidiasis 50 huperzine 50 VITAL Trial 50 AIM HIGH 50 ALGRX 50 PERSEUS clinical program 50 Multi Ethnic Study 50 efalizumab 50 thymalfasin 50 sNDA submission 50 Diabetic Macular Edema 50 Meets Primary Endpoint 50 CYT# QbG# 50 Prospective Randomized 50 STELARA 50 MabCampath 50 ribavirin RBV 50 fluvastatin 50 Pharmacokinetic Study 50 Azedra 50 neratinib 50 CLORETAZINE TM VNP#M 50 By JENNIFER LEARN 50 NATRECOR R 50 CEQ# 50 bevirimat Study 50 acute HAE attacks 50 investigational protease inhibitor 50 Tolerability 50 REVIVE TA 50 dexamethasone Decadron 50 Phase III ALLEGRO 50 REMINYL ® 50 subcutaneous dose 50 tapentadol ER 50 mg TID 50 romidepsin 50 FOLFOX 50 Protelos 50 AZILECT 50 Randomized Clinical Trial 50 lixisenatide 50 Communities ARIC study 50 PROPEL trial 50 beclomethasone dipropionate 50 Peginterferon 50 ginkgo biloba extract 50 INVEGA ® 50 EDEMA4 50 AVOREN 50 normotensive 50 Tracleer R 50 topical formulation 50 FASLODEX 50 azilsartan medoxomil 50 randomized discontinuation trial 50 Cholesterol Levels SPARCL 50 generalized anxiety disorder GAD 50 comparing alemtuzumab 50 evaluable subjects 50 GW# [003] 50 protease inhibitors PIs 49 PRoFESS 49 recurrent malignant glioma 49 lamotrigine 49 MoxDuo TM IR 49 ceftazidime 49 Diamyd R 49 Long Term Efficacy 49 ONGLYZA 49 mertansine 49 tasocitinib 49 Phase 2a Clinical Trial 49 milligram doses 49 MADIT II 49 Gabapentin GR 49 pain palliation 49 alfa 2a 49 EVIZON 49 Multicenter Phase 49 reslizumab 49 Mg Uk 49 CYPHER ® Sirolimus eluting 49 BENICAR 49 Clinical Outcomes Utilizing Revascularization 49 dihydroergotamine DHE 49 Subgroup Analysis 49 unique alkylating agent 49 deferiprone 49 Phase III metastatic melanoma 49 arzoxifene 49 pertuzumab 49 pharmacodynamic properties 49 Huperzine 49 PRISTIQ 49 allosteric modulator NAM 49 pharmacodynamic profiles 49 IMPACT IMmunotherapy 49 ARRY 49 trials BLISS 49 sequential dose escalation 49 RESOLUTE 49 AVERROES 49 Novel Oral 49 Zoraxel 49 ganetespib 49 tipranavir 49 RDEA# 49 ancrod 49 solithromycin 49 MAP# 49 HeFT 49 YONDELIS 49 EMPHASIS HF trial 49 SINGULAIR 49 COU AA 49 antihypertensive therapy 49 zileuton 49 Linagliptin 49 acute coronary syndromes ACS 49 pregabalin 49 latrepirdine 49 Mipomersen 49 Phase 2a proof 49 preclinical efficacy 49 elagolix 49 docetaxel chemotherapy 49 rilonacept 49 SCY 49 mg dosed once 49 valproate 49 plus gemcitabine 49 salmeterol fluticasone 49 primary generalized tonic 49 orally administered 49 investigational pan BCR 49 Locteron 49 subgroup analyzes 49 Naive Patients 49 HGS# 49 HF ACTION 49 PERSEUS 49 TO AVOID PREGNANCY WHILE 49 mcg 49 bolus injection 49 liposome injection 49 Phase III Trial 49 Tiotropium 49 landmark ATHENA study